Frankfurt
18.09.26 | 20:16
0,314 Euro
+15,44 % +0,042
1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,328 | 0,332 | 19:04 | |
| 0,314 | 0,340 | 18.09. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.09. | Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in Phase 1 Trial of CT-202 | 162 | GlobeNewswire (Europe) | CT-202 is a Nectin-4 x CD3 T cell engaging bispecific antibody Phase 1 trial is evaluating CT-202 as a monotherapy treatment in patients with urothelial, colorectal, and triple-negative breast cancers... ► Artikel lesen | |
| 06.08. | Context Therapeutics Stock (CNTX) is Falling After Hours: Here's What's Driving the Move | 11 | Benzinga.com | ||
| 06.08. | Context Therapeutics GAAP EPS of -$0.15 | 5 | Seeking Alpha | ||
| 31.07. | Context Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.07. | Context Therapeutics Inc.: Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 7 | GlobeNewswire (USA) | ||
| 06.07. | Context Therapeutics Inc.: Context Therapeutics Added to Russell 2000 and Russell 3000 Indexes | 6 | GlobeNewswire (USA) | ||
| CONTEXT THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.06. | Context Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 15.06. | Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study | 7 | Benzinga.com | ||
| 15.06. | Context Therapeutics Inc. - 8-K, Current Report | 5 | SEC Filings | ||
| 15.06. | Context Therapeutics Inc.: Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76 | 528 | GlobeNewswire (Europe) | 29% confirmed overall response rate per RECIST v1.1 in patients with platinum-resistant ovarian cancer ("PROC") who progressed on a median of 7 prior lines of therapy Cytokine Release Syndrome ("CRS")... ► Artikel lesen | |
| 09.06. | Context Therapeutics Inc.: Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 18.05. | Context Therapeutics Inc.: Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202 | 257 | GlobeNewswire (Europe) | Context announces buyout of CT-202 future milestones and royalties in exchange for a fully paid-up, non-terminable license Phase 1 initiation for CT-202 trial expected in third quarter of 2026 PHILADELPHIA... ► Artikel lesen | |
| 18.05. | Context Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.05. | Context Therapeutics reports Q1 results | 3 | Seeking Alpha | ||
| 06.05. | Context Therapeutics Inc.: Context Therapeutics Reports First Quarter 2026 Operating and Financial Results | 199 | GlobeNewswire (Europe) | Phase 1a interim data for ongoing CTIM-76 (CLDN6 x CD3) trial expected in June 2026 Phase 1a interim data for ongoing CT-95 (MSLN x CD3) trial expected in September 2026 Phase 1 initiation for CT-202... ► Artikel lesen | |
| 01.05. | Context Therapeutics Inc. - 8-K, Current Report | 4 | SEC Filings | ||
| 02.04. | Context Therapeutics rises on FDA fast track status for lead asset | 5 | Seeking Alpha | ||
| 02.04. | Context Therapeutics Inc.: Context Therapeutics Announces CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer | 468 | GlobeNewswire (Europe) | Fast Track Designation highlights potential of CTIM-76 to address unmet need for patients with PROC CTIM-76 Phase 1a trial ongoing, with interim data expected in June 2026 PHILADELPHIA, April 02,... ► Artikel lesen | |
| 02.04. | Context Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 23.03. | Context Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 83,80 | +0,18 % | BioNTech SE: Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge | Gotistobart zeigte weiterhin Potenzial als chemotherapiefreie Monotherapie zur Reaktivierung der Anti-Tumor-Immunität in bereits vorbehandelten Patientinnen und Patienten mit Plattenepithelkarzinom... ► Artikel lesen | |
| EVOTEC | 2,914 | +1,11 % | Neue Angriffspunkte gegen Krebs! Warum Vidac Pharma, BioNTech und Evotec Aufmerksamkeit verdienen! | Krebszellen nutzen ausgeklügelte Schutzmechanismen, entziehen sich dem Immunsystem und programmieren ihren eigenen Stoffwechsel um. Diese Mechanismen werden nun verstärkt zur Zielscheibe von Biotechgesellschaften.... ► Artikel lesen | |
| MEDIGENE | 0,005 | -3,70 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| AMGEN | 335,15 | -0,16 % | Amgen: FDA Approves Update To IMDELLTRA Prescribing Information, Cuts Monitoring Time For Two Doses | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced the FDA approved an update to the IMDELLTRA Prescribing Information that substantially reduces the recommended monitoring time for the first... ► Artikel lesen | |
| NOVAVAX | 8,670 | -1,37 % | Novavax: Langfristige Aussichten im Spannungsfeld von Innovation und Konkurrenz | ||
| BIOGEN | 189,04 | +0,74 % | Biogen Inc.: Phase 3 Pediatric EMPAVELI Data Published in Clinical Journal of the American Society of Nephrology Show Reduction in Proteinuria and Stabilized Kidney Function in Adolescents with C3G or Primary IC-MPGN | EMPAVELI-treated adolescents achieved a 75% relative reduction in proteinuria within 6 months versus placebo EMPAVELI is the only approved treatment for adolescents with C3G and primary IC-MPGN, based... ► Artikel lesen | |
| HEIDELBERG PHARMA | 2,470 | -0,40 % | Heidelberg Pharma AG-Aktie im Check am 18.09. (08:39 Uhr): Meine aktuelle Lageeinschätzung | ||
| BIOXXMED | 1,100 | 0,00 % | PTA-News: bioXXmed AG: Einladung zur Hauptversammlung | DJ PTA-News: bioXXmed AG: Einladung zur Hauptversammlung
Unternehmensmitteilung für den Kapitalmarkt
bioXXmed AG: Einladung zur Hauptversammlung
Heidelberg (pta000/20.07.2026/15:45... ► Artikel lesen | |
| VIVOSIM LABS | 0,223 | -1,67 % | VivoSim Labs, Inc.: VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs | ||
| INOVIO PHARMACEUTICALS | 1,077 | +9,40 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights | U.S. Food and Drug Administration (FDA) review of Biologics License Application (BLA) for INO-3107 as a treatment for Recurrent Respiratory Papillomatosis (RRP)... ► Artikel lesen | |
| CLINUVEL | 5,022 | -1,26 % | CLINUVEL PHARMACEUTICALS LIMITED: CLINUVEL date of Annual General Meeting | ||
| SANGAMO THERAPEUTICS | 0,126 | -100,00 % | Sangamo Therapeutics, Inc.: Sangamo Therapeutics Selects Successful Bidders Following Competitive Asset Auction for $163.55 Million in Cash Consideration at Closing and Up to $100 Million in Potential Milestones | PTC Therapeutics to purchase Fabry disease program, isaralgagene civaparvovec Lilly to purchase capsid delivery, zinc finger and modular integrase (MINT) platforms and prion disease program Proposed... ► Artikel lesen | |
| VIKING THERAPEUTICS | 25,100 | -0,59 % | Wall Street Sees a Huge Rebound for Viking Therapeutics. Here's Why Analysts Are So Optimistic. | ||
| INFLARX | 1,842 | +0,99 % | InflaRx NV-Aktie im Check am 20.09. (11:12 Uhr): Meine aktuelle Lageeinschätzung | ||
| INTELLIA THERAPEUTICS | 10,360 | -2,08 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million | CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing... ► Artikel lesen |
CONTEXT THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,314 Euro und damit +15,44 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CONTEXT THERAPEUTICS INC finden Sie auf Wallstreet Online.